Back to Search Start Over

Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Management

Authors :
Michele, Lioncino
Emanuele, Monda
Federica, Verrillo
Elisabetta, Moscarella
Giulio, Calcagni
Fabrizio, Drago
Bruno, Marino
Maria Cristina, Digilio
Carolina, Putotto
Paolo, CalabrĂ²
Maria Giovanna, Russo
Amy E, Roberts
Bruce D, Gelb
Marco, Tartaglia
Giuseppe, Limongelli
Lioncino, M.
Monda, E.
Verrillo, F.
Moscarella, E.
Calcagni, G.
Drago, F.
Marino, B.
Digilio, M. C.
Putotto, C.
Calabro, P.
Russo, M. G.
Roberts, A. E.
Gelb, B. D.
Tartaglia, M.
Limongelli, G.
Source :
Heart Fail Clin
Publication Year :
2022
Publisher :
Elsevier Inc., 2022.

Abstract

RASopathies are multisystemic disorders caused by germline mutations in genes linked to the RAS/mitogen-activated protein kinase pathway. Diagnosis of RASopathy can be triggered by clinical clues ("red flags") which may direct the clinician toward a specific gene test. Compared with sarcomeric hypertrophic cardiomyopathy, hypertrophic cardiomyopathy in RASopathies (R-HCM) is associated with higher prevalence of congestive heart failure and shows increased prevalence and severity of left ventricular outflow tract obstruction. Biventricular involvement and the association with congenital heart disease, mainly pulmonary stenosis, have been commonly described in R-HCM. The aim of this review is to assess the prevalence and unique features of R-HCM and to define the available therapeutic options.

Details

Language :
English
Database :
OpenAIRE
Journal :
Heart Fail Clin
Accession number :
edsair.pmid.dedup....b3fee0566f451bb2dc36a3fb0bbaf695